Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $56.00

Collegium Pharmaceutical (NASDAQ:COLL) had its target price raised by Needham & Company LLC from $48.00 to $56.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also weighed in on COLL. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. HC Wainwright restated a “buy” rating and set a $60.00 target price (up previously from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial set a $55.00 price objective on Collegium Pharmaceutical in a report on Wednesday. Finally, Barclays assumed coverage on Collegium Pharmaceutical in a research report on Monday, December 8th. They issued an “overweight” rating and a $58.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $45.54 on Thursday. The firm has a market capitalization of $1.44 billion, a PE ratio of 28.29 and a beta of 0.60. The stock’s fifty day moving average is $46.23 and its 200 day moving average is $38.54. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $50.79. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The business had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. On average, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This represents a 19.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the transaction, the director owned 52,629 shares in the company, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 51,250 shares of company stock worth $2,235,352. Company insiders own 2.51% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares in the last quarter. CWM LLC increased its holdings in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the period. Hantz Financial Services Inc. increased its holdings in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the period. EverSource Wealth Advisors LLC raised its stake in Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after buying an additional 2,169 shares during the period.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium issued 2026 financial guidance that topped consensus on revenue. Management expects product revenues of $805M–$825M (vs. consensus ~$782.9M) and adjusted EBITDA of $455M–$475M; Jornay PM net revenue is guided to $190M–$200M. This stronger-than-expected top‑line and profitability outlook is a clear positive catalyst. Collegium Provides 2026 Financial Guidance and Business Update
• Positive Sentiment: Needham raised its price target from $48 to $56 and maintained a “buy” rating, implying roughly 23% upside from the current level — a supportive analyst endorsement that can attract buyers. Benzinga TickerReport
• Neutral Sentiment: Barclays trimmed its price target slightly (from $58 to $56) but kept an “overweight” rating — a mixed signal that reduces upside expectations a bit while still indicating conviction in the name. Benzinga
• Neutral Sentiment: A broader industry piece highlighting branded pharmaceuticals and peer Q3 results mentions the group context for names like Collegium; useful for benchmarking but not specific company news. MSN: Branded pharmaceuticals stocks Q3 results
• Negative Sentiment: Zacks downgraded Collegium from “strong-buy” to “hold,” which may prompt some profit‑taking or limit fresh inflows from investors who follow Zacks ratings. Zacks TickerReport

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.